Envista executes on growth priorities with new products, acquisitions and global expansion, but macro, tariff and currency headwinds remain in focus.
Envista rises 37.1% in a year as new dental product launches, margin gains, acquisitions and a strong balance sheet fuel growth.
Envista (NVST) reported earnings 30 days ago. What's next for the stock?
| Health Care Equipment & Supplies Industry | Healthcare Sector | Paul A. Keel CEO | XDUS Exchange | US29415F1049 ISIN |
| US Country | 12,300 Employees | - Last Dividend | - Last Split | 18 Sep 2019 IPO Date |
Envista Holdings Corporation, along with its subsidiaries, embarks on designing, manufacturing, marketing, and distributing dental products across the United States, China, and internationally. Incorporated in 2018 and based in Brea, California, the company serves a diverse clientele in the dental field through its two primary segments: Specialty Products & Technologies, and Equipment & Consumables. It focuses on delivering innovative solutions to oral surgeons, prosthodontists, periodontists, general dentists, and orthodontists with a portfolio that includes dental implant systems, digital orthodontic treatments, dental equipment, and various consumable supplies.
The comprehensive offerings of Envista Holdings Corporation are categorized into two main segments, each comprising an array of products tailored to the needs of dental professionals:
This segment presents a variety of dental and orthodontic solutions, including:
Key brands under this segment include Nobel Biocare, Alpha-Bio Tec, Implant Direct, Ormco, Spark, and Orascoptic, among others.
This segment ensures dental professionals have the necessary equipment and supplies for their practices:
Notable brands within this segment include Dexis, Kerr, Metrex, and CaviWipes, aimed at equipping dental offices, clinics, and hospitals with top-grade dental products.